Lee Hye-young, the new CEO of Korea BMS Pharmaceuticals.

Lee Hye-young, the new CEO of Korea BMS Pharmaceuticals.

View original image


[Asia Economy Reporter Lee Gwan-joo] Korea BMS Pharmaceutical announced on the 26th that Lee Hye-young has been appointed as the new CEO effective August 10.


CEO Lee, who graduated from Seoul National University College of Pharmacy and earned an MBA from Korea University, has accumulated diverse experience and expertise through various departments including marketing, strategic planning, business development, and clinical research during her over 20 years at Pfizer. Her roles included CEO of Pfizer Korea Upjohn, CEO of Pfizer Singapore, and head of the cardiovascular treatment division for the APAC region. She was appointed Vice President of Pfizer Korea in 2017 and returned to Korea, and in 2020, she was appointed CEO of Viatris Korea.


Along with her role as CEO of Korea BMS Pharmaceutical, CEO Lee will also oversee BMS's cardiovascular disease division for the Asia cluster.



Meanwhile, the former CEO Kim Jin-young has been promoted to lead the Global BMS Compliance and Ethics Division, overseeing compliance strategies for the Intercontinental region. The Intercontinental region includes Asia excluding Japan, Australia, New Zealand, South America, the Middle East, Africa, Eastern Europe, Turkey, Israel, and India.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing